Key facts
- Isomorphic Labs aims to create drugs to cure cancer and other diseases.
- The company uses AI to predict how drug molecules interact with the body.
- Isomorphic plans to engineer molecules for minimum effective drug dosage.
- The company is focused on breakthrough drugs for cancer, immune system, and inflammatory diseases.
- Isomorphic has research partnerships with Novartis, Johnson & Johnson, and Eli Lilly.
Isomorphic Labs, a spinoff of Google DeepMind, is developing AI to design drugs for cancer and other diseases. President Max Jaderberg stated that AI will be integral to drug design within five years, with the company aiming to create novel medicines. The firm's AI models, including a new drug design engine that builds on AlphaFold, are intended to predict molecular interactions, optimize drug dosage, and minimize side effects. Isomorphic is focused on cancer, immune system, and inflammatory diseases and has research partnerships with Novartis, Johnson & Johnson, and Eli Lilly.